Yuguan Biotech

Delonix Bioworks (operating as Shanghai Yuguan Biotech) is a pioneering synthetic biology company focused on developing the next generation of bacterial vaccines and medicines. Based in Shanghai, the company leverages its proprietary pathogen genome engineering platforms—OMV Plus, BioDVax, and ProBVax—to rationally design bacteria and outer membrane vesicles (OMVs) for enhanced safety and efficacy. Its clinical-stage pipeline is led by DX-104, an engineered OMV vaccine for Meningococcal B, which has received IND clearance and entered Phase 1 testing. Beyond vaccines, Delonix aims to address antimicrobial resistance and oncology through its living medicine approach, supported by strategic partnerships with organizations like WuXi Vaccines and Olymvax.